7-year results of cell therapy in patients with severe ischemic cardiomyopathy

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Intracoronary infusion of autologous bone marrow cells (CTX) shows promise for improving myocardial function in post-infarct and chronic ischemic cardiomyopathy patients.
• Long-term outcomes of CTX therapy remain largely unknown, necessitating extended follow-up studies.

Purpose of the Study:

• To evaluate the long-term (7-year) effects of CTX on myocardial function and clinical outcomes in patients with chronic ischemic cardiomyopathy.
• To assess the safety and efficacy of CTX in a population with severely impaired left ventricular ejection fraction.

Main Methods:

• A pilot study involving eleven patients with chronic ischemic cardiomyopathy and low ejection fraction (19±1%) treated with CTX.
• Long-term follow-up for seven years, monitoring clinical status, cardiac function (ejection fraction, ventricular volumes), and adverse events.
• Assessment of clinical benefit using NYHA functional class and evaluation for reverse remodeling.

Main Results:

• Four out of eleven patients died from progressive heart failure during the 7-year follow-up.
• Left ventricular ejection fraction (19±1% pre, 18±6% post) and end-diastolic volumes (289±71 ml pre, 294±123 ml post) remained stable in survivors.
• Modest clinical benefit observed (NYHA 3.0 pre, 2.5 post; p=0.06), with no significant reverse remodeling.

Conclusions:

• CTX therapy in this cohort was associated with stabilization of ejection fraction and ventricular volumes over seven years.
• No significant long-term clinical benefit or evidence of reverse remodeling was demonstrated with CTX.
• CTX therapy appears safe in the long term for this patient population, with stability of cardiac parameters being the primary observed effect.